Reversal of the Antiplatelet Effects of Ticagrelor in Combination With Aspirin, Using Normal Platelets

• Status: Unknown status
• Trial end date: 2018-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The specific objective of this study is to investigate the potential for normal platelets to reverse the inhibition of platelet aggregation in patients treated with ticagrelor in combination with aspirin.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hamilton Health Sciences Corporation
• Treatments: Aspirin; Ticagrelor

Criteria

Inclusion Criteria:

• Healthy subjects

• At least 18 years of age

• No history of cardiovascular disease

• Not taking antiplatelet therapy prior to participation

Exclusion Criteria:

• Known thrombocytopenia, other coagulation disorder such as von Willebrand's disease, haemophilia

• Allergy or intolerance to ticagrelor or aspirin (if known)

• Consumption of drugs within the preceding fourteen days that potentially can interfere with metabolism of ticagrelor through CYP3A4, CYP3A or P-glycoprotein (eg, ketoconazole, clarithromycin, nefazodone, ritonavir, atazanavir, diltiazem, amprenavir, aprepitant, erythromycin, fluconazole, verapamil, rifampicin, dexamethasone, phenytoin, carbamazepine, phenobarbital, cyclosporine, simvastatin, atorvastatin, tolbutamide, digoxin)21

• Previous transfusion or pregnancy (because of potential alloimmunisation)

• Pregnant or trying to conceive, or breastfeeding

• Unable or unwilling to give written informed consent